Corvus Pharmaceuticals (CRVS) Competitors $3.24 +0.21 (+6.93%) Closing price 04:00 PM EasternExtended Trading$3.21 -0.03 (-0.93%) As of 07:19 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock CRVS vs. RCUS, VIR, MLYS, PAHC, SYRE, NRIX, ZYME, GYRE, DAWN, and AVXLShould you be buying Corvus Pharmaceuticals stock or one of its competitors? The main competitors of Corvus Pharmaceuticals include Arcus Biosciences (RCUS), Vir Biotechnology (VIR), Mineralys Therapeutics (MLYS), Phibro Animal Health (PAHC), Spyre Therapeutics (SYRE), Nurix Therapeutics (NRIX), Zymeworks (ZYME), Gyre Therapeutics (GYRE), Day One Biopharmaceuticals (DAWN), and Anavex Life Sciences (AVXL). These companies are all part of the "pharmaceutical products" industry. Corvus Pharmaceuticals vs. Arcus Biosciences Vir Biotechnology Mineralys Therapeutics Phibro Animal Health Spyre Therapeutics Nurix Therapeutics Zymeworks Gyre Therapeutics Day One Biopharmaceuticals Anavex Life Sciences Corvus Pharmaceuticals (NASDAQ:CRVS) and Arcus Biosciences (NYSE:RCUS) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their profitability, community ranking, dividends, valuation, earnings, analyst recommendations, media sentiment, risk and institutional ownership. Which has higher earnings and valuation, CRVS or RCUS? Corvus Pharmaceuticals has higher earnings, but lower revenue than Arcus Biosciences. Corvus Pharmaceuticals is trading at a lower price-to-earnings ratio than Arcus Biosciences, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioCorvus PharmaceuticalsN/AN/A-$27.03M-$0.97-3.34Arcus Biosciences$258M3.26-$307M-$3.10-2.58 Does the media favor CRVS or RCUS? In the previous week, Arcus Biosciences had 7 more articles in the media than Corvus Pharmaceuticals. MarketBeat recorded 9 mentions for Arcus Biosciences and 2 mentions for Corvus Pharmaceuticals. Corvus Pharmaceuticals' average media sentiment score of 1.22 beat Arcus Biosciences' score of 0.80 indicating that Corvus Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Corvus Pharmaceuticals 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Arcus Biosciences 5 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Which has more risk & volatility, CRVS or RCUS? Corvus Pharmaceuticals has a beta of 0.71, indicating that its share price is 29% less volatile than the S&P 500. Comparatively, Arcus Biosciences has a beta of 1.54, indicating that its share price is 54% more volatile than the S&P 500. Does the MarketBeat Community prefer CRVS or RCUS? Corvus Pharmaceuticals received 97 more outperform votes than Arcus Biosciences when rated by MarketBeat users. However, 65.33% of users gave Arcus Biosciences an outperform vote while only 62.08% of users gave Corvus Pharmaceuticals an outperform vote. CompanyUnderperformOutperformCorvus PharmaceuticalsOutperform Votes29362.08% Underperform Votes17937.92% Arcus BiosciencesOutperform Votes19665.33% Underperform Votes10434.67% Do analysts rate CRVS or RCUS? Corvus Pharmaceuticals currently has a consensus price target of $15.67, suggesting a potential upside of 383.54%. Arcus Biosciences has a consensus price target of $30.25, suggesting a potential upside of 277.94%. Given Corvus Pharmaceuticals' stronger consensus rating and higher probable upside, analysts plainly believe Corvus Pharmaceuticals is more favorable than Arcus Biosciences.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Corvus Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 1 Strong Buy rating(s) 3.25Arcus Biosciences 0 Sell rating(s) 1 Hold rating(s) 8 Buy rating(s) 1 Strong Buy rating(s) 3.00 Do institutionals & insiders believe in CRVS or RCUS? 46.6% of Corvus Pharmaceuticals shares are owned by institutional investors. Comparatively, 92.9% of Arcus Biosciences shares are owned by institutional investors. 31.3% of Corvus Pharmaceuticals shares are owned by company insiders. Comparatively, 12.3% of Arcus Biosciences shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth. Is CRVS or RCUS more profitable? Corvus Pharmaceuticals has a net margin of 0.00% compared to Arcus Biosciences' net margin of -102.66%. Arcus Biosciences' return on equity of -45.59% beat Corvus Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets Corvus PharmaceuticalsN/A -70.71% -45.90% Arcus Biosciences -102.66%-45.59%-22.38% SummaryArcus Biosciences beats Corvus Pharmaceuticals on 9 of the 17 factors compared between the two stocks. Remove Ads Get Corvus Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for CRVS and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart CRVS vs. The Competition Export to ExcelMetricCorvus PharmaceuticalsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$220.76M$6.32B$5.33B$7.57BDividend YieldN/A3.23%5.11%4.32%P/E Ratio-3.486.7921.7317.81Price / SalesN/A225.93379.1994.60Price / CashN/A65.6738.1534.64Price / Book4.105.866.464.00Net Income-$27.03M$141.86M$3.20B$247.23M7 Day Performance14.89%8.98%6.54%7.26%1 Month Performance-28.32%-12.65%-8.55%-6.26%1 Year Performance120.41%-11.99%10.33%-0.18% Corvus Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)CRVSCorvus Pharmaceuticals3.0368 of 5 stars$3.24+6.9%$15.67+383.5%+98.0%$220.76MN/A-3.4830Gap DownHigh Trading VolumeRCUSArcus Biosciences2.4672 of 5 stars$7.28+5.9%$30.25+315.8%-53.7%$764.88M$258M-2.31500High Trading VolumeVIRVir Biotechnology2.6529 of 5 stars$5.52-1.1%$35.67+546.1%-37.9%$757.03M$63.71M-1.41580Short Interest ↑MLYSMineralys Therapeutics2.5758 of 5 stars$12.05-2.8%$33.00+173.9%+7.0%$756.56MN/A-3.3128Insider TradeShort Interest ↑Positive NewsGap UpHigh Trading VolumePAHCPhibro Animal Health3.8186 of 5 stars$18.66-2.8%$21.00+12.5%+36.6%$755.79M$1.11B38.881,860SYRESpyre Therapeutics1.6486 of 5 stars$12.39-3.1%$50.33+306.2%-65.3%$746.58M$890,000.00-1.66100Gap DownHigh Trading VolumeNRIXNurix Therapeutics2.1103 of 5 stars$9.72+0.3%$30.88+217.7%-41.2%$741.01M$54.55M-3.36300Earnings ReportGap DownHigh Trading VolumeZYMEZymeworks2.6582 of 5 stars$10.43-4.7%$21.00+101.3%+18.9%$725.69M$76.30M-6.95460Positive NewsGYREGyre Therapeutics0.1282 of 5 stars$7.62+10.1%N/A-54.1%$713.32M$105.76M152.4040Short Interest ↑High Trading VolumeDAWNDay One Biopharmaceuticals2.4378 of 5 stars$7.02-2.8%$32.29+359.9%-47.6%$711.51M$131.16M-6.8260News CoverageAVXLAnavex Life Sciences3.3584 of 5 stars$8.33+1.7%$44.00+428.2%+105.4%$708.58MN/A-15.1540Gap Down Remove Ads Related Companies and Tools Related Companies Arcus Biosciences Alternatives Vir Biotechnology Alternatives Mineralys Therapeutics Alternatives Phibro Animal Health Alternatives Spyre Therapeutics Alternatives Nurix Therapeutics Alternatives Zymeworks Alternatives Gyre Therapeutics Alternatives Day One Biopharmaceuticals Alternatives Anavex Life Sciences Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:CRVS) was last updated on 4/15/2025 by MarketBeat.com Staff From Our PartnersGet Your Bank Account “Fed Invasion” Ready with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredElon Musk Confirms: Tesla’s Optimus is Replacing Workers… and Heading to MarsElon Musk just confirmed Tesla’s robot will go to Mars. But on Earth, it may trigger a trillion-dollar tech sh...InvestorPlace | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredTrump to redistribute trillions of dollars Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredDOGE tax surpriseElon Musk's DOGE agents have some very strange plans for the IRS... Recently, it emerged that our tax auth...Altimetry | SponsoredAmazon ShockerJeff Bezos quietly backing world-changing tech (not AI) The Amazon founder is quietly advancing a radical t...Stansberry Research | SponsoredCaught on Camera: Elon Musk’s “Area 51”You won’t believe what tech legend Jeff Brown found in what he calls Elon Musk’s “Area 51.” (Click here to see...Brownstone Research | SponsoredURGENT: Someone's Moving Gold Out of London...People who don’t understand the gold market are about to lose a lot of money. Unfortunately, most so-called “g...Golden Portfolio | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Corvus Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Corvus Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy CRVS Stock Free CRVS Stock Alerts